The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The association of PTEN loss on outcome in patients with early high-risk prostate cancer (CaP) treated with adjuvant docetaxel following radical prostatectomy (RP).
D. Keizman
No relevant relationships to disclose
Z. Zhang
No relevant relationships to disclose
V. J. Sinibaldi
No relevant relationships to disclose
A. DeMarzo
No relevant relationships to disclose
B. Gurel
No relevant relationships to disclose
T. Lotan
No relevant relationships to disclose
J. Hicks
No relevant relationships to disclose
E. Rosenbaum
No relevant relationships to disclose
E. S. Antonarakis
No relevant relationships to disclose
J. J. Kim
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose
M. A. Eisenberger
No relevant relationships to disclose